Analystreport

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $22.00 p

Dicerna Pharmaceuticals, Inc.  (DRNA) 
Last dicerna pharmaceuticals, inc. earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.dicerna.com